Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
19 September 2019

Abstract

Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.